Novo Nordisk A/S Stock price

Equities

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen 11:59:44 2024-03-18 am EDT 5-day change 1st Jan Change
914.2 DKK +1.13% Intraday chart for Novo Nordisk A/S +2.13% +30.96%
Sales 2024 * 287B 41.81B Sales 2025 * 345B 50.26B Capitalization 4,079B 595B
Net income 2024 * 103B 15.06B Net income 2025 * 124B 18.08B EV / Sales 2024 * 14.3 x
Net Debt 2024 * 25.84B 3.77B Net Debt 2025 * 2.2B 321M EV / Sales 2025 * 11.8 x
P/E ratio 2024 *
39.5 x
P/E ratio 2025 *
32.4 x
Employees 63,845
Yield 2024 *
1.29%
Yield 2025 *
1.55%
Free-Float 70.79%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Novo Nordisk A/S

1 day+1.13%
1 week+1.02%
Current month+11.53%
1 month+7.44%
3 months+37.72%
6 months+37.16%
Current year+30.96%
More quotes
1 week
883.50
Extreme 883.5
927.90
1 month
806.50
Extreme 806.5
932.00
Current year
688.80
Extreme 688.8
932.00
1 year
487.10
Extreme 487.1
932.00
3 years
210.08
Extreme 210.075
932.00
5 years
155.08
Extreme 155.075
932.00
10 years
109.10
Extreme 109.1
932.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 90-12-31
Director of Finance/CFO 53 98-12-31
Chief Tech/Sci/R&D Officer - 15-09-30
Members of the board TitleAgeSince
Director/Board Member 63 15-03-18
Chairman 61 17-03-22
Director/Board Member 68 18-02-28
More insiders
Date Price Change Volume
24-03-18 914.2 +1.13% 2,038,452
24-03-15 904 -2.22% 5,984,147
24-03-14 924.5 +2.10% 2,484,956
24-03-13 905.5 -1.02% 2,335,821
24-03-12 914.8 +2.20% 2,504,551

Delayed Quote Nasdaq Copenhagen, March 18, 2024 at 11:59 am EDT

More quotes
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes treatment products (78.9%); - rare disease treatment products (11.6%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.; - obesity treatment products (9.5%). Net sales are distributed geographically as follows: Europe/Middle East/Africa (25%), the United States (47.8%), North America (3.6%), China (9.2%) and other (14.4%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
914.2 DKK
Average target price
894.2 DKK
Spread / Average Target
-2.18%
Consensus
  1. Stock
  2. Equities
  3. Stock Novo Nordisk A/S - Nasdaq Copenhagen